Asia PacificENPublic regulatory overview
China
Market Overview Population: Approximately 1.41 billion (2024) Healthcare System: Predominantly public hospitals (threetier system with tertiary/Grade IIIA hospitals at the top), su...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingCore / local basisNMPA approval or filing is the local China market-access basis.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: China
- Product line: Medical devices
- Regulator / source: Regulatory Maturity: Highly mature. The regulatory framework has undergone intensive reform (major revisions in 2017, 2020, and 2021). Technical review capacity has improved rapidly, with a clear trend toward international alignment — though local implementation specifics remain distinctive.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 1.41 billion (2024)
- Healthcare System: Predominantly public hospitals (three-tier system with tertiary/Grade III-A hospitals at the top), supplemented by private hospitals and internet-based healthcare; universal basic health insurance coverage exceeds 95%
- Market Characteristics: World's second-largest medical device market, with an estimated market size of approximately CNY 1.2 trillion in 2023. Import substitution (국산화) policies are aggressively pursued; volume-based procurement (VBP) for high-value consumables has become routine. Grade III-A hospitals are the primary channel for premium devices; the grassroots/primary care market holds substantial growth potential.
- Regulatory Maturity: Highly mature. The regulatory framework has undergone intensive reform (major revisions in 2017, 2020, and 2021). Technical review capacity has improved rapidly, with a clear trend toward international alignment — though local implementation specifics remain distinctive.
Regulatory Authority
- Competent Authority: National Medical Products Administration (NMPA), formerly CFDA/SFDA
- Official Portals: https://www.nmpa.gov.cn; Medical Device Registration System: https://ectd.nmpa.gov.cn
- Key Regulations:
- Regulations for the Supervision and Administration of Medical Devices (2021 revision, State Council Decree No. 739)
- Administrative Measures for Medical Device Registration and Filing (2021, NMPA Order No. 47)
- Administrative Measures for Registration and Filing of In Vitro Diagnostic Reagents (2021, NMPA Order No. 48)
- Good Clinical Practice for Medical Device Clinical Trials (2022)
- Requirements and Instructions for Medical Device Registration Dossiers (category-specific guidance documents)
Device Classification System
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Class I | Low risk | EU Class I / FDA Class I | Filing (备案) system; handled by provincial drug regulatory authorities; clinical data generally not required |
| Class II | Moderate risk | EU Class IIa/IIb / FDA Class II | Registration system; approved by provincial authorities (some categories by NMPA); most require clinical evidence |
| Class III | High risk | EU Class III / FDA Class III/PMA | Registration system; technical review conducted directly by NMPA/CMDE; virtually all require clinical trial data or a clinical exemption |
Note: IVDs have a separate classification system (Class I through Class III), and classification criteria may differ from non-IVD devices. Refer to the Medical Device Classification Catalogue (2017 edition, with subsequent updates).
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.